A61K 31/341
Not condensed with another ring
Official title: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K31/341 (Not condensed with another ring) appears on 1,147 US grants and 1,887 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,147
- Published applications
- 1,887
- Assignees
- 975
- Inventors
- 3,921
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 15 | 0 |
| 1998 | 18 | 0 |
| 1999 | 12 | 0 |
| 2000 | 20 | 0 |
| 2001 | 21 | 16 |
| 2002 | 29 | 36 |
| 2003 | 17 | 47 |
| 2004 | 16 | 49 |
| 2005 | 17 | 38 |
| 2006 | 13 | 31 |
| 2007 | 16 | 38 |
| 2008 | 11 | 55 |
| 2009 | 18 | 51 |
| 2010 | 16 | 52 |
| 2011 | 22 | 60 |
| 2012 | 22 | 66 |
| 2013 | 35 | 78 |
| 2014 | 56 | 111 |
| 2015 | 76 | 135 |
| 2016 | 79 | 122 |
| 2017 | 94 | 113 |
| 2018 | 75 | 97 |
| 2019 | 75 | 92 |
| 2020 | 67 | 114 |
| 2021 | 70 | 98 |
| 2022 | 54 | 103 |
| 2023 | 50 | 72 |
| 2024 | 42 | 90 |
| 2025 | 50 | 71 |
| 2026 | 31 | 52 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Neurodevelopmental disorder therapy15 Sep 2026US 12,734,147 B2Anavex Life Sciences Corp.
- Compounds for the treatment of bacterial infections and potentiation of antibiotics8 Sep 2026US 12,728,105 B2Georgia State University Research Foundation, Inc.
- Functionalized Maleimides and Isomaleimides and a process for preparation thereof8 Sep 2026US 12,729,180 B2Council of Scientific and Industrial Research
- Combination therapy for VAV3 cancer18 Aug 2026US 12,708,627 B2Children's Hospital Medical Center
- Furan based compositions and methods of making thereof11 Aug 2026US 12,703,689 B2University of Delaware
- Use of small molecules to increase hypoxia inducible factor (hif) activity8 Oct 2026US 2026/0306440 A1Brown University
- Novel carboxamide derivatives8 Oct 2026US 2026/0308149 A1Angelini Pharma S.P.A.
- Hdac1/2 selective inhibitor and use thereof1 Oct 2026US 2026/0297110 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Composition for preventing or treating cancer, containing manassantin a and immune checkpoint inhibitor or epithelial growth factor receptor inhibitor17 Sep 2026US 2026/0272873 A1Kyungpook National University Industry-Academic Cooperation Foundation
- Animal treatments17 Sep 2026US 2026/0272905 A1NewMarket Pharmaceuticals LLC
Most cited
By later US patents
- Probiotic recolonisation therapy240US 8,460,648 B22013
- Taste-masked microcapsule compositions and methods of manufacture238US 6,139,865 AEurand America, Inc. · 2000
- Methods for treating inflammatory conditions167US 6,190,691 B1Adolor Corporation · 2001
- Method for enhancing outflow of aqueous humor in treatment of glaucoma151US 6,228,873 B1The Regents of the University of California · 2001
- Delivery system for an oral care substance using a strip of material having low flexural stiffness139US 6,096,328 AThe Procter & Gamble Company · 2000